| 恩度联合第3代含铂化疗方案治疗55例晚期非小细胞肺癌的临床观察 |
| |
| 引用本文： | 龙建林,李潞,黄媚娟,任莉,侯梅,王瑾,徐泳,彭枫,卢铀.恩度联合第3代含铂化疗方案治疗55例晚期非小细胞肺癌的临床观察[J].肿瘤,2010,30(2). |
| |
| 作者姓名： | 龙建林 李潞 黄媚娟 任莉 侯梅 王瑾 徐泳 彭枫 卢铀 |
| |
| 作者单位： | 四川大学华西医院肿瘤中心胸部肿瘤科,成都,610041 |
| |
| 摘 要： | 目的:观察重组人血管内皮抑制素恩度联合第3代含铂化疗方案治疗晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)的疗效、中位无进展生存(progression-free survival, PFS)时间和不良反应.方法:55例晚期NSCLC患者接受恩度联合第3代含铂化疗方案治疗,化疗至少2个周期以上.观察指标包括PFS、总有效率(response rate, RR)、临床获益率(clinical benefit rate, CBR)和不良反应.结果:在51例可评价疗效的患者中,15例(29.4%)获得部分缓解,27例(52.9%)为疾病稳定,9例(17.6%)为疾病进展,无完全缓解患者;RR为29.4%(15/51),CBR为82.4%(42/51).所有55例患者的中位PFS为6.3个月.不同病理类型(P = 0.370)、初治与复治(P = 0.101)、不同化疗方案(P = 0.232)患者的近期疗效差异无统计学意义,PFS差异也无统计学意义.研究期间总的白细胞和血小板下降率分别为72.7%和54.5%,Ⅲ～Ⅳ度白细胞和血小板计数下降率分别为36.4%和21.8%.有4例患者因不良反应退出研究,其中1例患者因消化管出血而死亡,1例患者发生Ⅲ度血压升高而未得到控制,1例患者发生室上性心率失常,1例患者发生Ⅳ度肝功能异常.结论:恩度联合第3代含铂化疗方案治疗晚期NSCLC的近期CBR较高,PFS有所延长,不良反应尚能耐受.
|
| 关 键 词： | 癌 非小细胞肺 重组人血管内皮抑制素类 抗肿瘤联合化疗方案 治疗结果 |
Clinical observation on the efficacy of Endostar combined with platin-based chemotherapy for 55 cases of advanced non-small cell lung cancer |
| |
| LONG Jian-lin,LI Lu,HUANG Mei-juan,REN Li,HOU Mei,WANG Jin,XU Yong,PENG Feng,LU You.Clinical observation on the efficacy of Endostar combined with platin-based chemotherapy for 55 cases of advanced non-small cell lung cancer[J].Tumor,2010,30(2). |
| |
| Authors: | LONG Jian-lin LI Lu HUANG Mei-juan REN Li HOU Mei WANG Jin XU Yong PENG Feng LU You |
| |
| Institution: | LONG Jian-lin,LI Lu,HUANG Mei-juan,REN Li,HOU Mei,WANG Jin,XU Yong,PENG Feng,LU You (Department of Thoracic Cancer,Cancer Center,West China Hospital,Sichuan University,Chengdu 610041,China) |
| |
| Abstract: | Objective:To observe the efficacy,median progression-free survival (PFS) and adverse reaction induced by rh-endostatin injection (Endostar) plus platin-based chemotherapy for advanced non-small cell lung cancer (NSCLC).Methods:Fifty five histologically or cytologically confirmed advanced NSCLC patients received Endostar combined with platin-based chemotherapy for more than 2 cycles. The evaluated parameters included PFS,response rate (RR),clinical benefit rate (CBR) and adverse reaction. Results:Of the 51 p... |
| |
| Keywords: | Carcinoma non-small cell lung Recombinant human vascular endostatins Antineoplastic combined chemotherapy protocols Treatment outcome |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
